September 15, 2012
Article
Tumor board assessments sharpen treatment recommendations.
September 11, 2012
Reducing time between diagnosis and evaluation by specialists is particularly important for aggressive and complex cancers.
Finding Credible Voices in the Lynch Syndrome Community
Understanding Your Stage 2 Lymphoma Diagnosis
FDA Approves Revuforj for R/R NPM1-Mutant AML
How Does FDA-Approved Blenrep Treat Multiple Myeloma?